Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2012 3
2013 2
2014 2
2015 1
2021 4
2022 8
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Sigonya
Page 1
Sisonke: reaching several goals together.
Preiser W, Fish T. Preiser W, et al. Lancet. 2022 Mar 19;399(10330):1095-1097. doi: 10.1016/S0140-6736(22)00482-2. Lancet. 2022. PMID: 35305727 Free PMC article. No abstract available.
Sisonke phase 3B open-label study: Lessons learnt for national and global vaccination scale-up during epidemics.
Goga AE, Bekker LG, Garrett N, Takuva S, Sanne I, Odhiambo J, Mayat F, Fairall L, Brey Z, Bamford L, Tanna G, Grey G. Goga AE, et al. S Afr Med J. 2021 Dec 24;112(2b):13486. S Afr Med J. 2021. PMID: 35140006 Clinical Trial.
Sisonke is a multicentre, open-label, single-arm phase 3B vaccine implementation study of healthcare workers (HCWs) in South Africa, with prospective surveillance for 2 years. The primary endpoint is the rate of severe COVID-19, including hospitalisations and deaths. The …
Sisonke is a multicentre, open-label, single-arm phase 3B vaccine implementation study of healthcare workers (HCWs) in South Africa, …
Allergic reactions to the Ad26.COV2.S vaccine in South Africa.
Peter J, Day C, Takuva S, Takalani A, Engelbrecht I, Garrett N, Goga A, Louw V, Opie J, Jacobson B, Sanne I, Gail-Bekker L, Gray G. Peter J, et al. J Allergy Clin Immunol Glob. 2021 Dec 9;1(1):2-8. doi: 10.1016/j.jacig.2021.12.002. eCollection 2022 Feb. J Allergy Clin Immunol Glob. 2021. PMID: 37780073 Free PMC article.
OBJECTIVE: We sought to detail allergic reactions reported during the Sisonke phase 3B study in South Africa. METHODS: A single dose of the Ad26.COV2.S vaccine was administered to 4,77,234 South African health care workers between February 17 and May 17, 2021. ...
OBJECTIVE: We sought to detail allergic reactions reported during the Sisonke phase 3B study in South Africa. METHODS: A single dose …
Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
Takuva S, Takalani A, Seocharan I, Yende-Zuma N, Reddy T, Engelbrecht I, Faesen M, Khuto K, Whyte C, Bailey V, Trivella V, Peter J, Opie J, Louw V, Rowji P, Jacobson B, Groenewald P, Dorrington RE, Laubscher R, Bradshaw D, Moultrie H, Fairall L, Sanne I, Gail-Bekker L, Gray G, Goga A, Garrett N; Sisonke study team. Takuva S, et al. PLoS Med. 2022 Jun 21;19(6):e1004024. doi: 10.1371/journal.pmed.1004024. eCollection 2022 Jun. PLoS Med. 2022. PMID: 35727802 Free PMC article. Clinical Trial.
BACKGROUND: Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study aimed to assess the safety and effective …
BACKGROUND: Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clin …
The voices of Izwi Lethu: Interview reflections on a newsletter collaboration between researchers and sex worker activists in South Africa and its life beyond the academy.
Schuler G, Rasebitse K. Schuler G, et al. Glob Public Health. 2022 Oct;17(10):2521-2529. doi: 10.1080/17441692.2022.2061555. Epub 2022 Jun 16. Glob Public Health. 2022. PMID: 35708977
The newsletter partnership began in 2015 and continued until Sisonke took over in 2019, fulfilling the newsletter's tagline 'a newsletter by sex workers for sex workers.' But did the collaboration help Sisonke promote social justice or benefit the participants? The …
The newsletter partnership began in 2015 and continued until Sisonke took over in 2019, fulfilling the newsletter's tagline 'a newsle …
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
Bekker LG, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, Kassanjee R, Collie S, Sanne I, Boulle A, Seocharan I, Engelbrecht I, Davies MA, Champion J, Chen T, Bennett S, Mametja S, Semenya M, Moultrie H, de Oliveira T, Lessells RJ, Cohen C, Jassat W, Groome M, Von Gottberg A, Le Roux E, Khuto K, Barouch D, Mahomed H, Wolmarans M, Rousseau P, Bradshaw D, Mulder M, Opie J, Louw V, Jacobson B, Rowji P, Peter JG, Takalani A, Odhiambo J, Mayat F, Takuva S, Corey L, Gray GE; Sisonke Protocol Team; Sisonke Study Team. Bekker LG, et al. Lancet. 2022 Mar 19;399(10330):1141-1153. doi: 10.1016/S0140-6736(22)00007-1. Lancet. 2022. PMID: 35305740 Free PMC article.
METHODS: In the single-arm, open-label, phase 3B implementation Sisonke study, health-care workers aged 18 years and older were invited for vaccination at one of 122 vaccination sites nationally. ...
METHODS: In the single-arm, open-label, phase 3B implementation Sisonke study, health-care workers aged 18 years and older were invit …
Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study).
Jacobson BF, Schapkaitz E, Takalani A, Rowji PF, Louw V, Opie J, Bekker LG, Garrett N, Goga A, Reddy T, Zuma NY, Sanne I, Seocharan I, Peter J, Robinson M, Collie S, Khan A, Takuva S, Gray G. Jacobson BF, et al. BMJ Med. 2023 Mar 23;2(1):e000302. doi: 10.1136/bmjmed-2022-000302. eCollection 2023. BMJ Med. 2023. PMID: 37063238 Free PMC article.
OBJECTIVE: To assess the rates of vascular thrombotic adverse events in the first 35 days after one dose of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in healthcare workers in South Africa and to compare these rates with those observed in the general population. DESI …
OBJECTIVE: To assess the rates of vascular thrombotic adverse events in the first 35 days after one dose of the Ad26.COV2.S vaccine (Janssen …
Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
Takalani A, Robinson M, Jonas P, Bodenstein A, Sambo V, Jacobson B, Louw V, Opie J, Peter J, Rowji P, Seocharan I, Reddy T, Yende-Zuma N, Khutho K, Sanne I, Bekker LG, Gray G, Garrett N, Goga A; Sisonke Study Team. Takalani A, et al. Vaccine. 2024 Feb 27;42(6):1195-1199. doi: 10.1016/j.vaccine.2024.01.066. Epub 2024 Jan 25. Vaccine. 2024. PMID: 38278629 Clinical Trial.
The Sisonke 2 study provided a homologous boost at least 6 months after administration of the priming dose of Ad26.COV2.S for healthcare workers enrolled on the Sisonke phase 3b implementation study. ...No cases of thrombosis with thrombocytopaenia syndrome were rep …
The Sisonke 2 study provided a homologous boost at least 6 months after administration of the priming dose of Ad26.COV2.S for healthc …
Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F, Smith M, Ganga Y, Jule Z, Reedoy K, Miya Y, Mthabela N, Magula NP, Lessells R, de Oliveira T, Gosnell BI, Abdool Karim S, Garrett N, Hanekom W, Bekker LG, Gray G, Blackburn JM, Moosa MS, Sigal A; COMMIT-KZN Team. Khan K, et al. Clin Infect Dis. 2022 Aug 24;75(1):e857-e864. doi: 10.1093/cid/ciab1008. Clin Infect Dis. 2022. PMID: 34893824 Free PMC article.
METHODS: We enrolled participants who were vaccinated through the SISONKE South African clinical trial of the Ad26.CoV2.S vaccine in healthcare workers (HCWs). ...
METHODS: We enrolled participants who were vaccinated through the SISONKE South African clinical trial of the Ad26.CoV2.S vaccine in …
Human rights violations against sex workers: burden and effect on HIV.
Decker MR, Crago AL, Chu SK, Sherman SG, Seshu MS, Buthelezi K, Dhaliwal M, Beyrer C. Decker MR, et al. Lancet. 2015 Jan 10;385(9963):186-99. doi: 10.1016/S0140-6736(14)60800-X. Epub 2014 Jul 22. Lancet. 2015. PMID: 25059943 Free PMC article. Review.
21 results